Ovarian Cancer Clinical Trials in Durham, North Carolina

9 studies are recruiting for ovarian cancer in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

   Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke Cancer Center ( Site 0012), Durham, North Carolina

   Locations

   163 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07318558 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. DESTINY-PANTUMOUR04

   This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

   Stage

   Not phased

   Ages

   18 to 130

   Site

   Research Site, Durham, North Carolina

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07124000 on ClinicalTrials.gov

4. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Institute, Durham, North Carolina

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

5. REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

   The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke Cancer Center, Durham, North Carolina

   Locations

   6 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06710548 on ClinicalTrials.gov

6. TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

   The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

   Stage

   Not phased

   Ages

   25 to 50

   Site

   Duke University Hospital, Durham, North Carolina

   Locations

   66 in total

   Run by

   University Medical Center Nijmegen

   See if you can join NCT04294927 on ClinicalTrials.gov

7. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

   Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Center/ DUMC, Durham, North Carolina

   Locations

   18 in total

   Run by

   Incyclix Bio

   See if you can join NCT05735080 on ClinicalTrials.gov

8. Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

   The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Duke, Durham, North Carolina

   Locations

   7 in total

   Run by

   Carevive Systems, Inc.

   See if you can join NCT05974150 on ClinicalTrials.gov

9. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Institute, Durham, North Carolina

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov